Increased dosage of the RUNX1/AML1 gene: A third mode of RUNX leukemia?

Critical Reviews in Eukaryotic Gene Expression

Volumn 15, Issue 3, 2005, Pages 217-228

  Osato, Motomi ^a,b   Ito, Yoshiaki ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

AML1; Down syndrome; Megakaryocyte; Runx; Trisomy 21

Indexed keywords

AML1 GENE; CHROMOSOME 21; CHROMOSOME TRANSLOCATION; DOWN SYNDROME; GENE; GENE DOSAGE; GENE LOCUS; GENE OVEREXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA; LEUKEMOGENESIS; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; REVIEW; RUNX1 GENE; TRISOMY 21; ACUTE LYMPHOCYTIC LEUKEMIA; ACUTE NONLYMPHOCYTIC LEUKEMIA; ANIMAL; B LYMPHOCYTE; GENE EXPRESSION REGULATION; GENETICS; LYMPHOMA; METABOLISM; MOUSE; RETROVIRUS; THROMBOCYTOPOIESIS;

BACH1 PROTEIN, HUMAN; BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; DNA BINDING PROTEIN; ERG PROTEIN, HUMAN; ETS2 PROTEIN, HUMAN; FANCONI ANEMIA PROTEIN; RUNX1 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR ETS 2; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX2;

ANIMALS; B-LYMPHOCYTES; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; CORE BINDING FACTOR ALPHA 1 SUBUNIT; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA-BINDING PROTEINS; DOWN SYNDROME; FANCONI ANEMIA COMPLEMENTATION GROUP PROTEINS; GATA1 TRANSCRIPTION FACTOR; GENE DOSAGE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LEUKEMIA, MEGAKARYOCYTIC, ACUTE; LYMPHOMA; MICE; PROTO-ONCOGENE PROTEIN C-ETS-2; RETROVIRIDAE; THROMBOPOIESIS; TRANS-ACTIVATORS;

EID: 33644916915     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukarGeneExpr.v15.i3.40     Document Type: Review

References (66)

1. Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci U S A. 1991;88:10431-4.
2. Golub T, Barker G, Bohlander S, Hiebert S, Ward D, Bray-Ward P, Morgan E, Raimondi S, Rowley J, Gilliland D. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 1995;92:4917-21.
3. Mitani K, Ogawa S, Tanaka T, Miyoshi H, Kurokawa M, Mano H, Yazaki Y, Ohki M, Hirai H. Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J. 1994;13:504-10.
4. Nucifora G, Begy CR, Erickson P, Drabkin HA, Rowley JD. The 3;21 translocation in myelodysplasia results in a fusion transcript between the AML1 gene and the gene for EAP, a highly conserved protein associated with the Epstein-Barr virus small RNA EBER 1. Proc Natl Acad Sci U S A. 1993;90:7784-8.
5. Liu P, Tarle SA, Hajra A, Claxton DF, Marlton P, Freedman M, Siciliano MJ, Collins FS. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science. 1993;261:1041-4.
6. Osato M, Asou N, Abdalla E, Hoshino K, Yamasaki H, Okubo T, Suzushima H, Takatsuki K, Kanno T, Shigesada K, Ito Y. Biallelic and heterozygous point mutations in the runt domian of the AML1/PEBP2α B gene associated with myeloblastic leukemia. Blood. 1999;93:1817-24.
7. Song W-J, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, Ratajczak J, Resende IC, Haworth C, Hock R, Loh M, Felix C, Roy D-C, Busque l, Kurnit D, Willman C, Gewirtz AM, Speck NA, Bushweller JH, Li FP, Gardiner K, Poncz M, Maris JM, Gilliland DG. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23:166-75.
8. Harada H, Harada Y, Niimi H, Kyo T, Kimura A, Inaba T. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood. 2004;103:2316-24.
9. Osato M. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene. 2004;23:4284-96.
10. Speck NA, Terryl S. A new transcription factor family associated with human leukemias. Crit Rev Eukaryot Gene Expr. 1995;5:337-64.
11. Hitzler J, Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer. 2005;5:11-20.
12. Watson M, Carroll A, Shuster J, Steuber C, Borowitz M, Behm F, Pullen D, Land V. Trisomy 21 in childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study (8602). Blood. 1993;82:3098-102.
13. Wei C, Yu I, Tzeng C, Fan F, Hsieh R, Chiou T, Liu J, Chen P. Trisomy 21 in acute myeloid leukemia. Cancer Genet Cytogenet. 1996;86:177-80.
14. Niini T, Kanerva J, Vettenranta K, Saarinen-Pihkala UM, Knuutila S. AML1 gene amplification: a novel finding in childhood acute lymphoblastic leukemia. Haematologica. 2000;85:362-6.
15. Roumier C, Fenaux P, Lafage M, Imbert M, Eclache VCP. New mechanisms of AML1 gene alteration in hematological malignancies. Leukemia. 2003;17:9-16.
16. Mikhail F, Serry K, Hatem N, Mourad Z, Farawela H, El Kaffash D, Coignet L, Nucifora G. AML1 gene over-expression in childhood acute lymphoblastic leukemia. Leukemia. 2002;16:658-68.
17. Preudhomme C, Warot-Loze D, Roumier C, Grardel-Duflos N, Garand R, Lai JL, Dastugue N, Macintyre E, Deni C, Bauters F, Kerckaert JP, Cosson A, Fenaux P. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood. 2000;96:2862-9.
18. Taketani T, Taki T, Takita J, Ono R, Horikoshi Y, Kaneko Y, Sako M, Hanada R, Hongo T, Hayashi Y. Mutation of the AML1/RUNX1 gene in a transient myeloproliferative disorder patient with Down syndrome. Leukemia. 2002;16:1866-7.
19. Cameron E, Blyth K, Hanlon L, Kilbey A, Mackay N, Stewart M, Terry A, Vaillant F, Wotton S, Neil J. The Runx genes as dominant oncogenes. Blood Cells Mol Dis. 2003;30:194-200.
20. Wotton S, Stewart M, Blyth K, Vaillant F, Kilbey A, Neil JC, Cameron ER. Proviral insertion indicates a dominant oncogenic role for Runx1/AML-1 in T-cell lymphoma. Cancer Res. 2002;62:7181-5.
21. Stewart M, Terry A, Hu M, O'Hara M, Blyth K, Baxter E, Cameron E, Onions DE, Neil JC. Proviral insertions induce the expression of bone-specific isoforms of PEBP2alphaA (CBFA1): evidence for a new myc collaborating oncogene. Proc Natl Acad Sci U S A. 1997;94:8646-51.
22. Stewart M, MacKay N, Cameron E, Neil J. The common retroviral insertion locus Dsi1 maps 30 kilobases upstream of the P1 promoter of the murine Runx3/Cbfa3/Aml2 gene. J Virol. 2002;76:4364-9.
23. Castilla L, Perrat P, Martinez N, Landrette S, Keys R, Oikemus S, Flanegan J, Heilman S, Garrett L, Dutra A, Anderson S, Pihan G, Wolff L, Liu P. Identification of genes that synergize with Cbfb-MYH11 in the pathogenesis of acute myeloid leukemia. Proc Natl Acad Sci U S A. 2004;101:4924-9.
24. Akagi K, Suzuki T, Stephens R, Jenkins N, Copeland N. RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res. 2004;32:D523-7.
25. Vaillant F, Blyth K, Terry A, Bell M, Cameron E, Neil J, Stewart M. A full-length Cbfa1 gene product perturbs T-cell development and promotes lymphomagenesis in synergy with myc. Oncogene. 1999;18:124-34.
26. Blyth K, Terry A, Mackay N, Vaillant F, Bell M, Cameron E, Neil J, Stewart M. Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene. 2001;20:295-302.
27. Kurokawa M, Tanaka T, Tanaka K, Ogawa S, Mitani K, Yazaki Y, Hirai H. Overexpression of the AML1 proto-oncoprotein in NIH3T3 cells leads to neoplastic transformation depending on the DNA-binding and transactivational potencies. Oncogene. 1996;12:883-92.
28. Frank RC, Sun X, Berguido FJ, Jakubowiak A, Nimer SD. The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1. Oncogene. 1999;18:1701-10.
29. Wotton S, Blyth K, Kilbey A, Jenkins A, Terry A, Bernardin-Fried F, Friedman A, Baxter E, Neil J, Cameron E. RUNX1 transformation of primary embryonic fibroblasts is revealed in the absence of p53. Oncogene. 2004;23:5476-86.
30. Planaguma J, Diaz-Fuertes M, Gil-Moreno A, Abal M, Monge M, Garcia A, Baro T, Thomson T, Xercavins J, Alameda F, Reventos J. A differential gene expression profile reveals overexpression of RUNX1/AML1 in invasive endometrioid carcinoma. Cancer Res. 2004;64:8846-53.
31. Hasle H, Clemmensen I, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet. 2000;355:165-9.
32. Ross J, Spector L, Robison L, Olshan A. Epidemiology of leukemia in children with Down syndrome. Pediatr Blood Cancer. 2005;44:8-12.
33. Bassal M, La M, Whitlock J, Sather H, Heerema N, Gaynon P, Stork L. Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer. 2005;44:21-8.
34. Gurbuxani S, Vyas P, Crispino J. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood. 2004;103:399-406.
35. Izraeli S. Leukaemia - a developmental perspective. Br J Haematol. 2004;126:3-10.
36. Zipursky A. Transient leukaemia - a benign form of leukaemia in newborn infants with trisomy 21. Br J Haematol. 2003;120:930-8.
37. Wechsler J, Greene M, McDevitt M, Anastasi J, Karp J, Le Beau M, Crispino J. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148-52.
38. Ahmed M, Sternberg A, Hall G, Thomas A, Smith O, O'Marcaigh A, Wynn R, Stevens R, Addison M, King D, Stewart B, Gibson B, Roberts I, Vyas P. Natural history of GATA1 mutations in Down syndrome. Blood. 2004;103:2480-9.
39. Mundschau G, Gurbuxani S, Gamis A, Greene M, Arceci R, Crispino J. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood. 2003;101:4298-300.
40. Hitzler J, Cheung J, Li Y, Scherer S, Zipursky A. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood. 2003;101:4301-4.
41. Rainis L, Bercovich D, Strehl S, Teigler-Schlegel A, Stark B, Trka J, Amariglio N, Biondi A, Muler I, Rechavi G, Kempski H, Haas O, Izraeli S. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood. 2003;102:981-6.
42. Xu G, Nagano M, Kanezaki R, Toki T, Hayashi Y, Taketani T, Taki T, Mitui T, Koike K, Kato K, Imaizumi M, Sekine I, Ikeda Y, Hanada R, Sako M, Kudo K, Kojima S, Ohneda O, Yamamoto M, Ito E. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood. 2003;102:2960-8.
43. Harigae H, Xu G, Sugawara T, Ishikawa I, Toki T, Ito E. The GATA1 mutation in an adult patient with acute megakaryoblastic leukemia not accompanying Down syndrome. Blood. 2004;103:3242-3.
44. Niitsu N, Yamamoto-Yamaguchi Y, Miyoshi H, Shimizu K, Ohki M, Umeda M, Honma Y. AML1a but not AML1b inhibits erythroid differentiation induced by sodium butyrate and enhances the megakaryocytic differentiation of K562 leukemia cells. Cell Growth Differ. 1997;8:319-26.
45. Michaud J, Wu F, Osato M, Cottles GM, Yanagida M, Asou N, Shigesada K, Ito Y, Benson KF, Raskind WH, Rossier C, Antonarakis SE, Israels S, McNicol A, Weiss H, Horwitz M, Scott HS. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood. 2002;99:1364-72.
46. Sun W, Downing J. Haploinsufficiency of AML1 results in a decrease in the number of LTR-HSCs while simultaneously inducing an increase in more mature progenitors. Blood. 2004;104:565-72.
47. Ichikawa M, Asai T, Saito T, Yamamoto G, Seo S, Yamazaki I, Yamagata T, Mitani K, Chiba S, Hirai H, Ogawa S, Kurokawa M. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med. 2004;10:299-304.
48. Elagib K, Racke F, Mogass M, Khetawat R, Delehanty L, Goldfarb A. RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood. 2003;101:4333-41.
49. Shimizu R, Takahashi S, Ohneda K, Engel J, Yamamoto M. In vivo requirements for GATA-1 functional domains during primitive and definitive erythropoiesis. EMBO J. 2001;20:5250-60.
50. Taniuchi I, Osato M, Egawa T, Sunshine M, Bae S, Komori T, Ito Y, Littman D. Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell. 2002;111:621-33.
51. McElwaine S, Mulligan C, Groet J, Spinelli M, Rinaldi A, Denyer G, Mensah A, Cavani S, Baldo C, Dagna-Bricarelli F, Hann I, Basso G, Cotter F, Nizetic D. Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker. Br J Haematol. 2004;125:729-42.
52. Antonarakis S, Lyle R, Dermitzakis E, Reymond A, Deutsch S. Chromosome 21 and Down syndrome: from genomics to pathophysiology. Nat Rev Genet. 2004;5:725-38.
53. Gjertson C, Sturm K, Berger C. Hematopoietic deficiencies and core binding factor expression in murine Ts16, an animal model for Down syndrome. Clin Immunol. 1999;91:50-60.
54. Kempski H, Craze J, Chessells J, Reeves B. Cryptic deletions and inversions of chromosome 21 in a phenotypically normal infant with transient abnormal myelopoiesis: a molecular cytogenetic study. Br J Haematol. 1998;103:473-9.
55. Yanagida M, Osato M, Yamashita N, Huang L, Jacob B, Wu F, Cao X, Nakamura T, Yokomizo T, Takahashi S, Yamamoto M, Shigesada K, Ito Y. Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice. Oncogene. 2005;24:4477-85.
56. Shimizu K, Ichikawa H, Tojo A, Kaneko Y, Maseki N, Hayashi Y, Ohira M, Asano S, Ohki M. An ets-related gene, ERG, is rearranged in human myeloid leukemia with t(16;21) chromosomal translocation. Proc Natl Acad Sci U S A. 1993;90:10280-4.
57. Shing D, McMullan D, Roberts P, Smith K, Chin S, Nicholson J, Tillman R, Ramani P, Cullinane C, Coleman N. FUS/ERG gene fusions in Ewing's tumors. Cancer Res. 2003;63:4568-76.
58. Rainis L, Rosenthal E, Strehl S, Haas OS, Izraeli S. The ERG gene in normal and malignant megakaryopoiesis. Blood;104:935a.
59. Sumarsono S, Wilson T, Tymms M, Venter D, Corrick C, Kola R, Lahoud M, Papas T, Seth A, Kola I. Down's syndrome-like skeletal abnormalities in Ets2 transgenic mice. Nature. 1996;379:534-7.
60. Toki T, Katsuoka F, Kanezaki R, Xu G, Kurotaki H, Sun J, Kamio T, Watanabe S, Tandai S, Terui K, Yagihashi S, Komatsu N, Igarashi K, Yamamoto M, Ito E. Transgenic expression of BACH1 transcription factor results in megakaryocytic impairment. Blood. 2005;105:3100-8.
61. Ives JH, Dagna-Bricarelli F, Basso G, Antonarakis SE, Jee R, Cotter F, Nizetic D. Increased levels of a chromosome 21-encoded tumor invasion and metastasis factor (TIAM1) mRNA in bone marrow of Down syndrome children during the acute phase of AML(M7). Gene Chrom Cancer. 1998;23:61-6.
62. Tassone F, Lucas R, Slavov D, Kavsan V, Crnic L, Gardiner K. Gene expression relevant to Down syndrome: problems and approaches. J Neural Transm. 1999;suppl 57:179-95.
63. Zhang Y, Nagata Y, Yu G, Nguyen H, Jones M, Toselli P, Jackson C, Tatsuka M, Todokoro K, Ravid K. Aberrant quantity and localization of Aurora-B/AIM-1 and survivin during megakaryocyte polyploidization and the consequences of Aurora-B/AIM-1-deregulated expression. Blood. 2004;103:3717-26.
64. Zimmet J, Ravid K. Polyploidy: occurrence in nature, mechanisms, and significance for the megakaryocyte-platelet system. Exp Hematol. 2000;28:3-16.
65. Liu W, Toyosawa S, Furuichi T, Kanatani N, Yoshida C, Liu Y, Himeno M, Narai S, Yamaguchi A, Komori T. Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J Cell Biol. 2001;155:157-66.
66. Bernardin-Fried F, Kummalue T, Leijen S, Collector M, Ravid K, Friedman A. AML1/RUNX1 increases during G1 to S cell cycle progression independent of cytokine-dependent phosphorylation and induces cyclin D3 gene expression. J Biol Chem. 2004;279:15678-87.